Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Revenue projections:

With Pfizer Inc.'s revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio	1.267000
forwardPE	9.596663
debtToEquity	74.253000
earningsGrowth	0.000000
revenueGrowth	0.026000
grossMargins	0.747160
operatingMargins	0.278770
trailingEps	0.760000
forwardEps	2.896840

PFE's current ratio, being 1.267, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, PFE is well-equipped to meet its immediate financial obligations without any difficulties.
Positive gross and operating margins for PFE suggest that the company is operating profitably. These margins highlight PFE's efficiency in managing costs while maintaining healthy revenue streams, contributing to its overall financial strength.

Price projections:

PFE's price has often been near the lower end of the projected range. This ongoing trend suggests that investor confidence might be waning, and the stock could face challenges in gaining upward momentum.

Insider Transactions:

2 Pfizer Inc. transactions were recorded, when the market price was 25.755000114440918.There were 2 transactions to buy PFE stock, with market price of 26.059999465942383.Pfizer Inc. has seen more buys than sells at its current price levels, which may suggest optimism among investors. This buying trend could indicate that the market expects a favorable performance for the stock in the near future.

Recommendation changes over time:

Analysts have shown a buy bias for PFE, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to PFE, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.